Report

vaccine market

Vaccine Market By Technology Type (Recombinant, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, and Other), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus, Polio, Hepatitis and Other) and End User (Pediatric, Adult and Traveler) and Geography – Global Forecast up to 2027

pages Pages: 91
tables Tables: 103
charts Charts: 73
country Regions/Countries: 4 / 10
compaines Companies: 10
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Vaccines, also known as immunizations, administered a weakened form of a disease into a person’s body, so the body starts producing antibodies or immunity against the disease. Adequate immunization has destroyed several diseases, such as polio and smallpox, with high death rates. Vaccinations play a vital role in maintaining the sustainable health of people among various countries; hence, they are adopted in various regional disease-prevention strategies. High incidence of diseases requiring vaccines and increasing use of vaccines for several infectious diseases, such as influenza, pneumonia, and rotavirus infection, are projected to significantly accelerate the global vaccines market's growth. In addition, the focus of governments on immunization programs helps promote awareness among people regarding the safety and availability of vaccines. Further, various technologies deployed in the development of effective vaccines foster the vaccine market growth. However, the high monetary inputs incurred in the vaccine development decline their adoption, thus impeding the market growth. The Vaccines Market is estimated to grow at the rate of 6.7% CAGR by 2027.  

Research Methodology:

The Vaccine Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Vaccines Market

Vaccines Market based on Technology Type

  • Recombinant
  • Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others

Vaccines Market based on Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus
  • Polio
  • Hepatitis
  • Other

Vaccines Market based on End-User

  • Pediatric
  • Adults
  • Travelers

Vaccines Market based on Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

On the basis of technology type, the conjugate vaccine segment has the primary share in the market. This is due to the rising government support along with the increasing company investments in conjugate vaccine development. In addition, conjugate vaccines are the most effective type of immunization, used to avoid diseases in both infants and adults, fueling the segment growth.

The market is further segmented based on the indication, in which diphtheria, pertussis, & tetanus segment hold a significant share in the market. The foremost share of this segment is attributed to the increasing number of cases of these diseases because of the increasing geriatric population and an increasing number of birth rates where these diseases are most likely to affect.

As per the market by end-user, the market is bifurcated into pediatrics, adults, and travelers. The pediatric segment has held a substantial share in the market, owing to the huge demand for vaccines among infants such as MMR vaccines, BCG vaccines, and DPT vaccines since infants are more prone to diseases where vaccines are mainly required.

According to the geographical market, the market is divided into North America, Europe, Asia Pacific, and the rest of the world. The North American region is registered for the largest share in the market. This is due to the high incidence of infectious diseases and rising investments by government and non-government organizations for vaccine development in the region.

In the present era, there are growing concerns about the spread of infectious diseases with the changing environment worldwide. These rising infectious diseases are pressure on public health but also affect global economies. The new diseases such as HIV, hepatitis, dengue have drawn considerable concern for the government of the respective countries. There is also an upturn of diseases assumed to be under control, such as malaria, cholera, and many more. Thus the rising number of dreadful infectious diseases and upturn of the diseases are creating a major growth in the vaccines market.

This report includes the company profiles of the Panacea Biotec Limited, Johnson & Johnson Services, Inc, VBI Vaccines Inc., Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline Plc, Sanofi S.A., PFIZER INC, NOVAVAX, INC., and Bavarian Nordic.

As a result, vaccines have emerged as an effective solution for the rising infectious diseases worldwide. Various governments of several countries are substantially investing in developing effective vaccines for a surging number of diseases worldwide.

  • Several factors are presented in this report which are influencing the market growth and limiting the market.
  • This report covers the segmentation and sub-segmentations and their contribution to the market's growth.
  • The report includes profiles of the key competitors in the vaccine market and their strategies such as product launches, company expansions, and acquisitions.
  • Further, the penetration of the market in the various countries is also depicted in this report.
  1. Executive Summary
  2. Industry Outlook
    1. Industry Overview
    2. Industry Trends
  3. Market Snapshot
    1. Market Definition
    2. Market Outlook
      1. Porter Five Forces
    3. Related Markets
  4. Market characteristics
    1. Market Overview
    2. Market Segmentation
    3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
    4. DRO - Impact Analysis
  5. Technology Type: Market Size & Analysis
    1. Overview
    2. Recombinant
    3. Conjugate Vaccines
    4. Live Attenuated Vaccines
    5. Inactivated Vaccines
    6. Toxoid Vaccines
    7. Others
  6. Indication: Market Size & Analysis
    1. Overview
    2. Pneumococcal Disease
    3. Influenza
    4. Human Papilloma Virus
    5. Meningococcal Disease
    6. Rotavirus
    7. Varicella, Measles, Mumps, & Rubella
    8. Diphtheria, Pertussis, & Tetanus
    9. Polio
    10. Hepatitis
    11. Other
  7. End-User: Market Size & Analysis
    1. Overview
    2. Pediatric
    3. Adults
    4. Travelers
  8. Geography: Market Size & Analysis
    1. Overview
    2. North America
    3. Europe
    4. Asia Pacific
    5. Rest of the World
  9. Competitive Landscape
    1. Competitor Comparison Analysis
    2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
  10. Vendor Profiles
    1. Panacea Biotec Limited
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    2. Johnson & Johnson Services, Inc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    3. VBI Vaccines Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    4. Merck & Co., Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    5. Astellas Pharma Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    6. GlaxoSmithKline Plc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    7. Sanofi S.A.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    8. PFIZER INC
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    9. NOVAVAX, INC.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    10. Bavarian Nordic
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
  11. Analyst Opinion
  12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
      1. Data Collation and In-house Estimation
      2. Market Triangulation
      3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations

TABLE 1.           GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 2.           GLOBAL VACCINES MARKET VALUE FOR RECOMBINANT, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3.           GLOBAL VACCINES MARKET VALUE FOR CONJUGATE VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4.           GLOBAL VACCINES MARKET VALUE FOR LIVE ATTENUATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5.           GLOBAL VACCINES MARKET VALUE FOR INACTIVATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6.           GLOBAL VACCINES MARKET VALUE FOR TOXOID VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7.           GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8.           GLOBAL VACCINES MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9.           GLOBAL VACCINES MARKET VALUE FOR PNEUMOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10.         GLOBAL VACCINES MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11.         GLOBAL VACCINES MARKET VALUE FOR HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12.         GLOBAL VACCINES MARKET VALUE FOR MENINGOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13.         GLOBAL VACCINES MARKET VALUE FOR ROTAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 14.         GLOBAL VACCINES MARKET VALUE FOR VARICELLA, MEASLES, MUMPS, & RUBELLA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 15.         GLOBAL VACCINES MARKET VALUE FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 16.         GLOBAL VACCINES MARKET VALUE FOR POLIO, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 17.         GLOBAL VACCINES MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 18.         GLOBAL VACCINES MARKET VALUE FOR OTHER, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 19.         GLOBAL VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 20.         GLOBAL VACCINES MARKET VALUE FOR PEDIATRIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 21.         GLOBAL VACCINES MARKET VALUE FOR ADULTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 22.         GLOBAL VACCINES MARKET VALUE FOR TRAVELERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 23.         NORTH AMERICA VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 24.         NORTH AMERICA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 25.         NORTH AMERICA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 26.         NORTH AMERICA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 27.         U.S VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 28.         U.S VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 29.         U.S VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 30.         CANADA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 31.         CANADA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 32.         CANADA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 33.         EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 34.         EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 35.         EUROPE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 36.         EUROPE VACCINES MARKET VALUE, END-USER, 2021-2027 (USD BILLION)

TABLE 37.         GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 38.         GERMANY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 39.         GERMANY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 40.         U.K VACCINES  MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 41.         U.K VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 42.         U.K VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 43.         FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 44.         FRANCE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 45.         FRANCE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 46.         ITALY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 47.         ITALY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 48.         ITALY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 49.         SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 50.         SPAIN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 51.         SPAIN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 52.         ROE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 53.         ROE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 54.         ROE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 55.         ASIA PACIFIC VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 56.         ASIA PACIFIC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 57.         ASIA PACIFIC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 58.         ASIA PACIFIC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 59.         CHINA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 60.         CHINA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 61.         CHINA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 62.         INDIA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 63.         INDIA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 64.         INDIA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 65.         JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 66.         JAPAN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 67.         JAPAN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 68.         REST OF APAC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 69.         REST OF APAC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 70.         REST OF APAC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 71.         REST OF WORLD VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)

TABLE 72.         REST OF WORLD VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 73.         REST OF WORLD VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)

TABLE 74.         PANACEA BIOTEC LIMITED: FINANCIALS          

TABLE 75.         PANACEA BIOTEC LIMITED: PRODUCTS & SERVICES    

TABLE 76.         PANACEA BIOTEC LIMITED: RECENT DEVELOPMENTS  

TABLE 77.         JOHNSON & JOHNSON SERVICES, INC: FINANCIALS    

TABLE 78.         JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES          

TABLE 79.         JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS         

TABLE 80.         VBI VACCINES INC: FINANCIALS         

TABLE 81.         VBI VACCINES INC: PRODUCTS & SERVICES    

TABLE 82.         VBI VACCINES INC: RECENT DEVELOPMENTS  

TABLE 83.         MERCK & CO., INC: FINANCIALS          

TABLE 84.         MERCK & CO., INC: PRODUCTS & SERVICES    

TABLE 85.         MERCK & CO., INC: RECENT DEVELOPMENTS   

TABLE 86.         ASTELLAS PHARMA INC: FINANCIALS  

TABLE 87.         ASTELLAS PHARMA INC: PRODUCTS & SERVICES         

TABLE 88.         ASTELLAS PHARMA INC: RECENT DEVELOPMENTS       

TABLE 89.         GLAXOSMITHKLINE PLC: FINANCIALS  

TABLE 90.         GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES        

TABLE 91.         GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS       

TABLE 92.         SANOFI S.A.: FINANCIALS       

TABLE 93.         SANOFI S.A.: PRODUCTS & SERVICES 

TABLE 94.         SANOFI S.A.: RECENT DEVELOPMENTS

TABLE 95.         PFIZER INC: FINANCIALS         

TABLE 96.         PFIZER INC: PRODUCTS & SERVICES   

TABLE 97.         PFIZER INC: RECENT DEVELOPMENTS  

TABLE 98.         NOVAVAX, INC: FINANCIALS    

TABLE 99.         NOVAVAX, INC: PRODUCTS & SERVICES          

TABLE 100.       NOVAVAX, INC: RECENT DEVELOPMENTS        

TABLE 101.       BAVARIAN NORDIC: FINANCIALS         

TABLE 102.       BAVARIAN NORDIC: PRODUCTS & SERVICES   

TABLE 103.       BAVARIAN NORDIC: RECENT DEVELOPMENTS

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Vaccine Market By Technology Type (Recombinant, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, and Other), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus, Polio, Hepatitis and Other) and End User (Pediatric, Adult and Traveler) and Geography – Global Forecast up to 2027
Interested in this report?
Get your FREE sample now!
DOWNLOAD NOW

Select User License

$
Request For Sample Report
Enquire Before Buying

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports
Card image cap
Genital Herpes Treatment Market by Type of Drugs (Acyclovir,...
$ 4000
Card image cap
Compounding Pharmacy Market by Therapeutic Areas (Hormone Re...
$ 4000
Card image cap
Attention Deficit Hyperactivity Market by Drug Type (Stimula...
$ 4000
Card image cap
Heparin Sales Market By Type (Low Molecular Weight Heparin, ...
$ 4000
Card image cap
Yeast Infection Market based on Pathogen Type (Candida albic...
$ 4000
Card image cap
Infectious Disease Therapeutics Market on the basis of Mode ...
$ 4000